Caterina Giannini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8501422/publications.pdf

Version: 2024-02-01

168 papers	15,816 citations	31976 53 h-index	18130 120 g-index
170 all docs	170 docs citations	170 times ranked	16651 citing authors

#	Article	IF	Citations
1	Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulinâ€"a novel tumor checkpoint controller targeting microtubules. Neuro-Oncology, 2022, 24, 384-395.	1.2	7
2	The Alliance AMBUSH Trial: Rationale and Design. Cancers, 2022, 14, 414.	3.7	5
3	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathologica, 2022, 143, 403-414.	7.7	13
4	Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort. Cancers, 2022, 14, 979.	3.7	9
5	Brachial plexus lipomatosis with perineurial pseudoonion bulb formation: Result of a mosaic PIK3CA mutation in the paraâ€axial mesoderm state. Brain Pathology, 2022, 32, e13057.	4.1	4
6	Longâ€term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients. International Forum of Allergy and Rhinology, 2022, 12, 1457-1467.	2.8	7
7	Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances, 2022, 4, .	0.7	2
8	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. American Journal of Surgical Pathology, 2022, 46, 1277-1283.	3.7	3
9	Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. Annals of Diagnostic Pathology, 2022, 59, 151967.	1.3	3
10	DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival. Acta Neuropathologica, 2022, 144, 155-157.	7.7	10
11	Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 2022, 144, 373-376.	7.7	7
12	ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations andTP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i4-i4.	1.2	0
13	Biology and grading of pleomorphic xanthoastrocytomaâ€"what have we learned about it?. Brain Pathology, 2021, 31, 20-32.	4.1	32
14	CODEL: phase III study of RT, RTâ€‰+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467.	1.2	58
15	Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary, 2021, 24, 192-206.	2.9	25
16	Association of amyloid angiopathy with microbleeds in logopenic progressive aphasia: an imagingâ€pathology study. European Journal of Neurology, 2021, 28, 670-675.	3.3	6
17	Expanding the spectrum of EWSR1â€PATZ1 rearranged CNS tumors: An infantile case with leptomeningeal dissemination. Brain Pathology, 2021, 31, e12934.	4.1	11
18	Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years. Journal of Neuropathology and Experimental Neurology, 2021, 80, 804-806.	1.7	0

#	Article	IF	Citations
19	TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?. Neuro-Oncology, 2021, 23, 865-866.	1.2	12
20	Comparison on epidemiology, tumor location, histology, and prognosis of intracranial germ cell tumors between Mayo Clinic and Japanese consortium cohorts. Journal of Neurosurgery, 2021, 134, 446-456.	1.6	21
21	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. Neurocase, 2021, 27, 212-222.	0.6	4
22	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
23	Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. American Journal of Pathology, 2021, 191, 602-617.	3.8	30
24	A Comprehensive Study of Spindle Cell Oncocytoma of the Pituitary Gland: Series of 6 Cases and Meta-Analysis of 85 Cases. World Neurosurgery, 2021, 149, e197-e216.	1.3	4
25	Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-Oncology, 2021, 23, 2042-2053.	1.2	37
26	Toward a better definition of focal cortical dysplasia: An iterative histopathological and genetic agreement trial. Epilepsia, 2021, 62, 1416-1428.	5.1	54
27	The Third Eye Sees Double: Cohort Study of Clinical Presentation, Histology, Surgical Approaches, and Ophthalmic Outcomes in Pineal Region Germ Cell Tumors. World Neurosurgery, 2021, 150, e482-e490.	1.3	11
28	Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing. Journal of Neuropathology and Experimental Neurology, 2021, 80, 764-768.	1.7	4
29	Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study. Journal of Neuro-Oncology, 2021, 154, 121-130.	2.9	3
30	Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation. Journal of Neuropathology and Experimental Neurology, 2021, 80, 821-829.	1.7	13
31	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
32	Intracranial angiomatoid fibrous histiocytoma with rhabdoid features: a mimic of rhabdoid meningioma. Brain Tumor Pathology, 2021, 38, 138-144.	1.7	9
33	Brain ischemic injury in COVIDâ€19â€infected patients: a series of 10 postâ€mortem cases. Brain Pathology, 2021, 31, 205-210.	4.1	61
34	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	7.7	7
35	SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA. Frontiers in Genetics, 2021, 12, 739054.	2.3	9
36	Optic Nerve Choristoma Mimicking a Neurenteric Cyst. American Journal of Neuroradiology, 2021, 42, 228-232.	2.4	2

#	Article	IF	Citations
37	Delaying Postoperative Radiotherapy in Low-Grade Esthesioneuroblastoma: Is It Worth the Wait?. Journal of Neurological Surgery, Part B: Skull Base, 2021, 82, e166-e171.	0.8	1
38	Diffuse Large B-Cell Lymphoma of Peripheral Nerve with Distinctive Pathological Features Resembling Primary CNS Lymphoma. Journal of Neuropathology and Experimental Neurology, 2021, , .	1.7	0
39	Trigeminal Amyloidoma: A Report of Two Cases and Review of the Literature. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, 620-626.	0.8	4
40	Intracranial cellular schwannomas: a clinicopathological study of 20 cases. Histopathology, 2020, 76, 275-282.	2.9	9
41	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathologica, 2020, 139, 277-286.	7.7	36
42	Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neuro-Oncology Advances, 2020, 2, vdaa109.	0.7	15
43	TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants. Clinical Neurology and Neurosurgery, 2020, 196, 106059.	1.4	5
44	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurology, 2020, 77, 1420.	9.0	109
45	Novel Diagnostic Methods and Posttreatment Clinical Phenotypes Among Intracranial Germ Cell Tumors. Neurosurgery, 2020, 87, 563-572.	1.1	18
46	Adult diffuse glioma GWAS by molecular subtype identifies variants inD2HGDHandFAM20C. Neuro-Oncology, 2020, 22, 1602-1613.	1.2	19
47	Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of â€œdual-genotypeâ€•IDH-mutant infiltrating gliomas. Acta Neuropathologica, 2020, 139, 1105-1107.	7.7	8
48	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
49	Long-term remission, relapses and maintenance therapy in adult primary central nervous system vasculitis: A single-center 35-year experience. Autoimmunity Reviews, 2020, 19, 102497.	5.8	29
50	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clinical Cancer Research, 2020, 26, 1094-1104.	7.0	124
51	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
52	Primary papillary epithelial tumour of the sella: expanding the spectrum of TTFâ€1â€positive sellar lesions. Neuropathology and Applied Neurobiology, 2020, 46, 493-505.	3.2	8
53	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
54	Epidemiology, natural history, and optimal management of neurohypophyseal germ cell tumors. Journal of Neurosurgery, 2020, , 1-9.	1.6	23

#	Article	IF	Citations
55	Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers. , 2020, , 127-138.		2
56	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. Journal of Neuropathology and Experimental Neurology, 2019, 78, 791-797.	1.7	50
57	Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology, 2019, 61, 1327-1332.	2.2	48
58	A phase 1 and randomized, placeboâ€controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer, 2019, 125, 3790-3800.	4.1	51
59	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro-Oncology, 2019, 21, 1458-1469.	1.2	47
60	Anaplastic Ependymoma and Posterior Fossa Grouping in a Patient With H3K27ME3 Loss of Expression but Chromosomal Imbalance. Advances in Radiation Oncology, 2019, 4, 466-472.	1.2	1
61	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	1.2	49
62	Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathologica Communications, 2019, 7, 139.	5.2	12
63	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	7.6	37
64	Using germline variants to estimate glioma and subtype risks. Neuro-Oncology, 2019, 21, 451-461.	1.2	23
65	Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. Autoimmunity Reviews, 2019, 18, 399-405.	5.8	17
66	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	27.8	129
67	Granular cell astrocytoma: an aggressive <scp>IDH</scp>â€wildtype diffuse glioma with molecular genetic features of primary glioblastoma. Brain Pathology, 2019, 29, 193-204.	4.1	7
68	Alternative lengthening of telomeres, ATRX loss and H3â€K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathology, 2019, 29, 126-140.	4.1	54
69	The impact of histopathology and NAB2â€“STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathologica, 2019, 137, 307-319.	7.7	44
70	Primary central nervous system vasculitis mimicking brain tumor: Comprehensive analysis of 13 cases from a single institutional cohort of 191 cases. Journal of Autoimmunity, 2019, 97, 22-28.	6.5	20
71	Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. European Journal of Endocrinology, 2019, 180, 127-134.	3.7	80
72	Glioblastoma of the cerebellopontine angle and internal auditory canal mimicking a peripheral nerve sheath tumor: case report. Journal of Neurosurgery, 2019, 131, 1835-1839.	1.6	10

#	Article	IF	Citations
73	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathologica, 2018, 135, 639-642.	7.7	281
74	Glioneuronal Heterotopia Presenting as Cerebellopontine Angle Tumor of Cranial NerveÂVIII. World Neurosurgery, 2018, 114, 289-292.	1.3	7
75	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-Oncology, 2018, 20, 546-556.	1.2	93
76	Primary central nervous system vasculitis associated with lymphoma. Neurology, 2018, 90, e847-e855.	1.1	22
77	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica, 2018, 135, 481-484.	7.7	145
78	Radiation-Induced Cavernous Malformations After Single-Fraction Meningioma Radiosurgery. Operative Neurosurgery, 2018, 15, 207-212.	0.8	12
79	Lowâ€grade fibromyxoid sarcoma arising within the median nerve. Neuropathology, 2018, 38, 309-314.	1.2	3
80	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. American Journal of Surgical Pathology, 2018, 42, 506-511.	3.7	43
81	The dangers of the â€œHead Downâ€•position in patients with untreated pituitary macroadenomas: case series and review of literature. Pituitary, 2018, 21, 231-237.	2.9	0
82	Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. Journal of Neuro-Oncology, 2018, 137, 583-591.	2.9	26
83	Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathologica, 2018, 135, 299-301.	7.7	51
84	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
85	Intracranial myxoid mesenchymal tumors with EWSR1â€“CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity?. Brain Pathology, 2018, 28, 183-191.	4.1	72
86	Recurrent copy number alterations in lowâ€grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathology, 2018, 28, 172-182.	4.1	64
87	WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary <scp>CNS</scp> tumours. Neuropathology and Applied Neurobiology, 2018, 44, 163-171.	3.2	47
88	Is the bloodâ€“brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology, 2018, 20, 184-191.	1.2	443
89	A case of oligodendroglioma and multiple sclerosis: Occamâ€™s razor or Hickamâ€™s dictum?. BMJ Case Reports, 2018, 2018, bcr-2018-225318.	0.5	3
90	Sellar Region Atypical Teratoid/Rhabdoid Tumors in Adults: Clinicopathological Characterization of Five Cases and Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1115-1121.	1.7	21

#	Article	IF	Citations
91	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1039-1054.	1.7	105
92	A Pediatric Intra-Axial Malignant SMARCB1-Deficient Desmoplastic Tumor Arising in Meningioangiomatosis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 883-889.	1.7	7
93	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Journal of the National Cancer Institute, 2018, 110, 1123-1132.	6.3	83
94	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	7.7	56
95	Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Modern Pathology, 2018, 31, 1787-1800.	5.5	24
96	A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nature Communications, 2018, 9, 2949.	12.8	183
97	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
98	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	1.2	99
99	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. American Journal of Neuroradiology, 2017, 38, 678-684.	2.4	63
100	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica, 2017, 133, 1001-1016.	7.7	245
101	Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 068-074.	0.8	21
102	Management of diffuse low-grade gliomas in adults â€" use of molecular diagnostics. Nature Reviews Neurology, 2017, 13, 340-351.	10.1	95
103	Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma. World Neurosurgery, 2017, 103, 655-663.	1.3	55
104	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
105	Case-based review: primary central nervous system lymphoma. Neuro-Oncology Practice, 2017, 4, 46-59.	1.6	3
106	Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. World Neurosurgery, 2017, 108, 997.e9-997.e14.	1.3	4
107	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. Radiographics, 2017, 37, 2164-2180.	3.3	105
108	Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence. Journal of Digital Imaging, 2017, 30, 469-476.	2.9	167

#	Article	IF	Citations
109	Synchronous Tumors of the Cerebellopontine Angle. World Neurosurgery, 2017, 98, 632-643.	1.3	8
110	Can Intraneural Perineuriomas Occur Intradurally? An Anatomic Perspective. Neurosurgery, 2017, 80, 226-234.	1.1	3
111	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
112	Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. Acta Neuropathologica, 2017, 134, 317-319.	7.7	3
113	Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. Brain Pathology, 2016, 26, 206-214.	4.1	25
114	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	9.0	21
115	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathologica, 2016, 132, 149-151.	7.7	127
116	Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report. Clinical Neurology and Neurosurgery, 2016, 150, 177-180.	1.4	17
117	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Annals of Neurology, 2016, 79, 437-447.	5.3	148
118	Adenoid Cystic Carcinoma Metastatic to the Pituitary: A Case Report and Discussion of Potential Diagnostic Value of Magnetic Resonance Elastography in Pituitary Tumors. World Neurosurgery, 2016, 91, 669.e11-669.e14.	1.3	10
119	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
120	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
121	NAB2-STAT6Gene Fusion in Meningeal Hemangiopericytoma and Solitary Fibrous Tumor. Journal of Neuropathology and Experimental Neurology, 2016, 75, 263-271.	1.7	63
122	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
123	Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2016, 75, 44-52.	1.7	63
124	24â€¥earâ€Old Woman with Recent Onset Back Pain. Brain Pathology, 2015, 25, 786-787.	4.1	0
125	Glioma Groups Based on 1p/19q,IDH, andTERTPromoter Mutations in Tumors. New England Journal of Medicine, 2015, 372, 2499-2508.	27.0	1,632
126	Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance). Neuro-Oncology Practice, 2015, 2, 199-204.	1.6	16

#	Article	IF	Citations
127	Pleomorphic Xanthoastrocytoma: Natural History and Longâ€Term Followâ€Up. Brain Pathology, 2015, 25, 575-586.	4.1	188
128	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology, 2015, 17, 1261-1269.	1.2	126
129	Solitary Metastasis to the Facial/Vestibulocochlear Nerve Complex: Case Report andÂReview of the Literature. World Neurosurgery, 2015, 84, 1178.e15-1178.e18.	1.3	2
130	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
131	Mycophenolate mofetil in primary central nervous system vasculitis. Seminars in Arthritis and Rheumatism, 2015, 45, 55-59.	3.4	30
132	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Journal of Neuro-Oncology, 2015, 124, 413-420.	2.9	27
133	Case-Based Review: newly diagnosed glioblastoma. Neuro-Oncology Practice, 2015, 2, 106-121.	1.6	13
134	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology, 2015, 84, 148-158.	1.1	49
135	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget, 2015, 6, 30295-30305.	1.8	113
136	CNS Lymphoma. Journal of Neuropathology and Experimental Neurology, 2014, 73, 478-494.	1.7	92
137	Interictal Scalp Electroencephalography and Intraoperative Electrocorticography in Magnetic Resonance Imagingâ€“Negative Temporal Lobe Epilepsy Surgery. JAMA Neurology, 2014, 71, 702.	9.0	45
138	Rhabdoid-like meningioma with inclusions consisting of accumulations of complex interdigitating cell processes rather than intermediate filaments. Acta Neuropathologica, 2014, 127, 937-939.	7.7	4
139	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH. Journal of Clinical Oncology, 2014, 32, 783-790.	1.6	356
140	Bizarre Semiology and Medically Intractable Seizures. Seminars in Pediatric Neurology, 2014, 21, 154-159.	2.0	0
141	Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathologica Communications, 2013, 1, 20.	5.2	52
142	A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nature Genetics, 2012, 44, 1122-1125.	21.4	131
143	Primary central nervous system vasculitis: pathology and mechanisms. Acta Neuropathologica, 2012, 123, 759-772.	7.7	130
144	Periventricular white matter immunoglobulin lambda light chain deposition disease diagnosed by proteomic analysis. Acta Neuropathologica, 2012, 124, 293-295.	7.7	4

#	Article	IF	Citations
145	Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathologica, 2012, 123, 295-319.	7.7	525
146	Reply: A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with initial normal magnetic resonance imaging. Brain, 2011, 134, e183-e183.	7.6	0
147	Intravascular mucinosis: a rare cause of cerebral infarction. Acta Neuropathologica, 2011, 121, 785-788.	7.7	1
148	Maintaining Clinical Tissue Archives and Supporting Human Research: Challenges and Solutions. Archives of Pathology and Laboratory Medicine, 2011, 135, 347-353.	2.5	13
149	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology, 2008, 18, 360-369.	4.1	125
150	Experimental gliomas in mice using the Sleeping Beauty (SB) transposon system: neuropathologic aspects. FASEB Journal, 2008, 22, 172.4.	0.5	1
151	Retrospective survival comparison of patients with cerebral versus cerebellar glioblastomas. FASEB Journal, 2008, 22, 706.7.	0.5	0
152	Histopathologic grading of adult medulloblastomas. Cancer, 2007, 109, 2557-2565.	4.1	34
153	N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology, 2007, 25, 2004-2004.	1.6	11
154	A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. Cancer Research, 2006, 66, 9852-9861.	0.9	678
155	Phase II trial of irinotecan (CPT-11) and radiation followed by irinotecan and BCNU in glioblastoma patients (pts). Journal of Clinical Oncology, 2006, 24, 1562-1562.	1.6	0
156	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology, 2005, 7, 164-176.	1.2	296
157	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. Journal of Clinical Oncology, 2004, 22, 1508-1508.	1.6	2
158	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. Journal of Clinical Oncology, 2004, 22, 1508-1508.	1.6	4
159	Gliomas of childhood. Pathologica, 2003, 95, 237.	3.4	0
160	Immunophenotype of Pleomorphic Xanthoastrocytoma. American Journal of Surgical Pathology, 2002, 26, 479-485.	3.7	107
161	Choristoma of the Optic Nerve: Case Report. Neurosurgery, 2002, 50, 1125-1128.	1.1	39
162	Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading. Journal of Neuropathology and Experimental Neurology, 2001, 60, 248-262.	1.7	186

#	Article	IF	Citations
163	Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics, 2001, 3, 159-162.	1.4	55
164	Pleomorphic xanthoastrocytoma. Cancer, 1999, 85, 2033-2045.	4.1	312
165	Cellular Proliferation in Pilocytic and Diffuse Astrocytomas. Journal of Neuropathology and Experimental Neurology, 1999, 58, 46-53.	1.7	156
166	Pleomorphic xanthoastrocytoma. Cancer, 1999, 85, 2033-2045.	4.1	74
167	Pleomorphic xanthoastrocytoma: what do we really know about it?. Cancer, 1999, 85, 2033-45.	4.1	91
168	Ultrastructural Morphometric Analysis of Human Sural Nerve Biopsies. Diabetic Medicine, 1996, 13, 675-676.	2.3	1